David W retweeted
1/10
#NephJC #TenPostNephJC.
#NephTwitter
📺 Video Decision Support and Advance Care Planning in Older Adults with Advanced Kidney Disease
⚖️Can a video decision aid help patients with dialysis decisions?
Read the article 👇 VIDEO KD
10.1001/jamainternmed.2026.5989
David W retweeted
$NVO $lly This is potency data from Eloralintide and zenagamtide early publications. Both molecules were compared to cagrilintide in their respective papers, the cross-paper fold relationships hold to within a factor of ~2x.
So cagrilintide and petrelintide look pretty similar on this basis
I have been wondering why zena appears so uniquely toxic. Zenagamtide has low potency overall at any ctr family receptor and is the least selective between amyr1 and ctr. But it has full potency at glp-1. Probably part of why its so toxic, they are hitting glp-1 so hard to get a small amyr1 benefit? Besides the short t1/2 (3.5 days) which also means I have to acutely spike the concentration to get sufficient coverage for the week. I also wonder what the effect is of having a single large molecule as opposed to cagrilintide+semaglutide which can distribute differently.
Basically every single thing about this peptide seems badly designed.
David W retweeted
🔔Elora+Tzp Phase 2 T2D was presented at Obesity Week today. This was presented at EASD 2026 earlier this fall, but they gave us more background today.
INTRO
▪️Set the stage by reviewing the Eloralintide’s potency at the AMY1R receptor vs both CTR and AMY3R, establishing it as a selective amylin agonist
▪️Reviewed Elora’s 48 week Phase 2 performance on its own (up to 20% WL) and the recent P1 Elora + Tirz data (up to 29% WL at 31 weeks) - both in obesity without T2D
▪️Prior best performance in T2D for weight-loss was 16% at 72 weeks (using tirzepatide)
RESULTS (48 weeks) - Efficacy estimand
▪️Elora alone - 8-12% WL, 1.1-1.4% A1C reduction
▪️EloraTZP (3/6mg Elora) - 19-23% WL, 2.6-2.9% A1C reductio
💥NEW INFO💥
▪️BMI targets: On highest EloraTzp dose, 46% reached BMI <= 25 (Baseline BMI of 40) 😲
▪️AE DC reasons🙌: 1 EloraTzp + 1 Tzp for weight reduction, 4 EloraTzp for decreased appetite, 5 EloraTzp for nausea, 2 EloraTzp vomiting
▪️Pulse rates dropped on Elora alone, rose on TZP, and were in the middle for EloraTzp
▪️Body composition changes: Fat loss index (% of WL from fat): Elora alone - 60-66%, EloraTzp (3/6mg) - ~70%, Tzp + Add on Elora 60%
▪️Prevalence of side effects
▪️Prevalence and severity of fatigue
Pick Tirz, Elora or Reta and look at week 8! All of them are about ~7% average weight loss! Just meaningless marketing talk here from Novo. Most people respond quickly to these newer generation meds!
#PRESS Novo’s CagriSema analyses show 67.8% of people studied are early responders, achieving ≥5% weight loss by week 8. Adults with overweight or obesity also reported meaningful quality of life improvements in physical function. Learn more in the press release here: novonordisk.com/content/nnco…
Cagrisema in Redefine 9...worse tolerability at lower doses than Survodutide and that's with more flexible titration. It's not as good for A1c as tirzepatide, and even the lower doses have over double the rate of SE/AE as tirzepatide. I can't see myself prescribing this often.
Now we can put Foundayo in the pile for OSA as well. Average weight loss at 52 weeks was 11.5% in a heavily male cohort.
investor.lilly.com/news-rele…
At some point I'll provide a deeper analysis of this data but the key point the authors make?
This is slightly more effective than bariatric surgery at reducing osteoarthritis knee pain. No incision required just one dose per week.
Presented at #ACR26:
The WOMAC pain score and body weight decreased significantly more with retatrutide than with placebo in patients with painful knee osteoarthritis and obesity. Full results of the phase 3 TRIUMPH-4 and TRIUMPH-1-OA trials: nej.md/4A4V4OK
@ACRheum

ALT A graph from the Original Article "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.” The trial names, TRIUMPH-4 and TRIUMPH-1-OA, are in parentheses after the title. The graph shows the change in WOMAC pain subscale score among participants in TRIUMPH-4. The trial results are being presented at the American College of Rheumatology Annual Meeting. The logo of the New England Journal of Medicine is at the bottom.
The Lp(a) trial was very flawed. They over treated their own population by lowering the LDL so much and then *shocked Pikachu* face found a null result.
But look in the appendix and those with LDL>100 had a small signal.
Plus 20% DC rate! And only 73% reduction in Lp(a)
Today #AHA26 and @NEJM the 2 big trials of secondary prevention of heart disease with an IL-6 antibody and Lp(a) antisense oligonucleotide. No beneficial effect, overall and across all subgroups
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE…
David W retweeted
1/10 #NephJC #TenPosts
🫘 Intermittent HD or continuous RRT for critically ill patients with AKI?
⚖️ For years, trials suggested similar outcomes. Does the choice of modality affect survival?
💥 The ICRAKI trial challenges previous evidence
nejm.org/doi/10.1056/NEJMoa2…
David W retweeted
ICRAKI- intermittent vs continuous RRT for AKI in the ICU? VA by @farahwehbe92
#NephTwitter #NephJC
nephjc.com/news/icraki-the-v…
David W retweeted
IHD vs CRRT again. ICRAKI was stopped early due to higher mortality with IHD. Real signal or truncation artifact? And was IHD given the way we'd give it to a patient on vasopressors? #NephJC #nephtwitter
✍️ By @rn_flex @DivyaveerSSNeph
nephjc.com/news/icraki11126
David W retweeted
#nephjc coverage of #kidneywk simultaneous publications day 1✨✨
✍️By @hswapnil @DrAkshayaJ @CristinaDeReins @dra_miliflores
nephjc.com/news/2026/10/21/k…
Cuz me and Jen are nerds. Couple notes here. The length of trial indicates they're planning for 30% weight loss as the average which is nuts. RIP Bariatric surgery.
Also change in GFR. Elora ⬆️ GFR in phase 2 data
For DM2 composite >15% WL AND A1c <6.5% is ambitious AF
🚨 EloraTZP AMPLIFY-1 and -2 Phase 3 trials have posted to clinical trials. 100 weeks! Wow! 😲
▪️AMPLIFY-1: Overweight/Obesity without T2D, 2100 patients and 8 ARMS!!! (5 Elora TZP, 1 Elora, 1 Tirz, and 1 placebo)
▪️AMPLIFY-2: Overweight/Obesity with T2D, 1000 patients and 2 arms (no placebo!). EloraTZP and Tirzepatide alone
Estimated end dates: End of 2029
AMPLIFY-1
clinicaltrials.gov/study/NCT…
AMPLIFY-2
clinicaltrials.gov/study/NCT…
2
15
905
First blush thought. Reta but more diarrhea, nausea/vomiting signal looks weird, increased lipase 15-20% is 🧐🧐 worth watching. Heart rate increases up to 10BPM, 6MG arm confounded ~25% of patients never took 6mg dose. Probably viable molecule but it'll be 3 years too late.
3
18
2,520
David W retweeted
If someone miraculously invented a drug that:
- successfully reversed obesity and most of its associated diseases
- improved longevity
- decreased the long term health costs
….and it was NOT covered by health insurance, ….
- then what would be the use of health insurance?
Can an oral small molecule provide renal and cardiovascular benefits just like the injectable GLP1 meds? The answer is probably so! New blog post today about Achieve 4 the CV trial that was presented at EASD.
the-incretins.beehiiv.com/p/…
David W retweeted
Managing iron-deficiency anemia is a challenge in CKD. This randomized trial in #ASNCJASN found that adding lactoferrin to oral iron improved hemoglobin and iron status more than iron alone, suggesting a potentially accessible treatment strategy. kidney.pub/CJASN11204





































